Cardio Diagnostics Holdings (NASDAQ: CDIO) is taking its cardiovascular disease prevention message directly to employers and benefits professionals this June, participating in four national benefits conferences to discuss innovative approaches to risk assessment and cost management. The company's engagement comes as cardiovascular disease remains one of the most expensive health conditions in the United States, driving significant healthcare spending for employers and insurers.
According to the American Heart Association, direct cardiovascular healthcare costs accounted for approximately 11% of all U.S. healthcare expenditures in 2020–2021, more than any other major diagnostic group. A single heart attack or major cardiovascular event can have consequences that extend far beyond a patient's health, affecting employers through higher medical costs, lost productivity, and long-term care expenses. Organizations responsible for employee benefits are increasingly seeking new strategies to identify risk earlier and improve outcomes.
Cardio Diagnostics has developed a suite of solutions designed to provide earlier identification of cardiovascular risk and enable more targeted interventions and preventive care. By engaging directly with stakeholders at these conferences, the company aims to help employers tackle the growing burden of cardiovascular disease on their healthcare costs and workforce productivity.
The company's participation in the benefits conferences underscores a broader trend: employers are becoming more proactive in managing chronic disease risks among their employees. With healthcare costs continuing to rise, early detection and prevention of cardiovascular events can lead to substantial savings for employers and better health outcomes for employees.
For more information about Cardio Diagnostics and its solutions, visit the company's newsroom at https://ibn.fm/CDIO. Full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
Forward-looking statements in this article involve risks and uncertainties, including those detailed in the company's filings with the SEC. Undue reliance should not be placed on forward-looking statements, which are based on information available as of the date hereof. All parties undertake no duty to update this information unless required by law.
